title: A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.
abstract: OBJECTIVE
  Panobinostat, a pan-deacetylase inhibitor, is a promising anti-cancer agent that increases acetylation of proteins associated with growth and survival pathways of malignant cells. The primary objective of this phase I dose-escalation study was to determine the maximum tolerated dose (MTD) of intravenous (i.v.) panobinostat administered on different dosing schedules in patients with advanced solid tumors or lymphoma. Secondary objective was to characterize safety and tolerability, pharmacokinetic profiles, and activities of the i.v. formulation.
  
  
  METHODS
  i.v. panobinostat was administered at escalating doses on a daily (days 1-3 and 8-10 of a 21-day cycle; days 1-3 and 15-17 of a 28-day cycle) or weekly (days 1, 8, and 15 of a 28-day cycle; days 1 and 8 of a 21-day cycle) schedule, and safety and tolerability were monitored. Serial blood samples were collected following dosing for pharmacokinetic and pharmacodynamic analyses.
  
  
  RESULTS
  The MTD for the daily administration schedule was 7.2 g/m(2), whereas the MTD for the weekly schedule was 20.0 mg/m(2). In addition to fatigue and cardiac arrhythmias, including prolonged QTcF, DLTs associated with the study drug were principally due to myelosuppressive effects. Maximum concentrations and bioavailability of i.v. panobinostat increased dose-proportionally across all doses evaluated.
  
  
  CONCLUSIONS
  Based on the results of this study and others, the i.v. formulation of panobinostat was well tolerated in many patients, but concerns remain regarding its potential suitability outside the study setting due to potential electrocardiogram abnormalities. Therefore, further development will focus on the panobinostat oral formulation.
authors: Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive, Suite 3380, Salt Lake City, UT 84103, USA. sunil.sharma@hci.utah.edu
authors: Sunil
authors: S
authors: Sharma
authors: Joachim
authors: J
authors: Beck
authors: Monica
authors: M
authors: Mita
authors: Sofia
authors: S
authors: Paul
authors: Margaret M
authors: MM
authors: Woo
authors: Margaret
authors: M
authors: Squier
authors: Brian
authors: B
authors: Gadbaw
authors: H Miles
authors: HM
authors: Prince
mesh_terms: D000107:Acetylation; D061605:Administration, Intravenous; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003710:Demography; D004305:Dose-Response Relationship, Drug; D005260:Female; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D000077767:Panobinostat; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007211:Indoles; D000077767:Panobinostat
references: Eur J Cancer. 2009 Jan;45(2):228-47
references: 19097774
references: J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47
references: 9262252
references: Cardiol Rev. 2004 Jul-Aug;12(4):222-34
references: 15191637
references: Nat Rev Drug Discov. 2006 Sep;5(9):769-84
references: 16955068
references: Science. 2009 Aug 14;325(5942):834-40
references: 19608861
references: Stat Med. 1998 May 30;17(10):1103-20
references: 9618772
references: Clin Cancer Res. 2006 Jun 15;12(12):3762-73
references: 16778104
references: Cancer Res. 2008 Jun 15;68(12):4833-42
references: 18559531
references: Clin Cancer Res. 2008 Jul 15;14(14):4500-10
references: 18628465
references: Cancer Treat Rep. 1979 Apr;63(4):725-8
references: 445521
references: Leuk Lymphoma. 2003;44 Suppl 3:S55-61
references: 15202526
references: Clin Cancer Res. 2006 Jan 15;12(2):634-42
references: 16428510
references: Cancer Res. 2006 Jun 1;66(11):5781-9
references: 16740717
references: Stat Med. 2008 Jun 15;27(13):2420-39
references: 18344187
references: J Clin Oncol. 2008 Jan 10;26(2):332-3; discussion 333-4
references: 18182676
references: Nat Rev Cancer. 2006 Jan;6(1):38-51
references: 16397526
references: J Biol Chem. 2005 Jul 22;280(29):26729-34
references: 15937340
references: Br J Haematol. 2010 Jan;148(2):256-67
references: 19874311
references: Cell. 2004 Nov 12;119(4):555-66
references: 15537544
references: Clin Cancer Res. 2006 Aug 1;12(15):4628-35
references: 16899611
references: Clin Cancer Res. 2008 Jun 1;14(11):3589-97
references: 18519793
references: Cancer Chemother Pharmacol. 2011 Sep;68(3):805-13
references: 21706316
references: J Clin Oncol. 1999 Apr;17(4):1244
references: 10561185
references: Nat Rev Cancer. 2001 Dec;1(3):194-202
references: 11902574
references: Chromosome Res. 2006;14(1):5-16
references: 16506092
references: Br J Dermatol. 2003 Dec;149(6):1095-1107
references: 14696593
references: Clin Cancer Res. 2009 Nov 15;15(22):7077-84
references: 19887475
references: J Clin Oncol. 2007 Jul 20;25(21):3109-15
references: 17577020
references: Clin Epigenetics. 2010 Dec;1(3-4):117-136
references: 21258646
references: Cell. 1997 Aug 22;90(4):595-606
references: 9288740
references: Cancer Res. 2006 Sep 1;66(17):8814-21
references: 16951198
references: Nat Rev Drug Discov. 2002 Apr;1(4):287-99
references: 12120280
references: Cell. 1999 Aug 6;98(3):285-94
references: 10458604
references: Cancer Res. 2008 Sep 15;68(18):7561-9
references: 18794144